| Line Item | 2025-06-30 | Y/Y |
|---|---|---|
| R&D Expense | $18.3M | +17.4% |
| SG&A Expense | $23.4M | +235.3% |
| Operating Income | -$41.8M | -85.7% |
| Net Income | -$37.9M | -74.3% |
| EPS (Basic) | -$1.05 | +80.9% |
| EPS (Diluted) | -$1.05 | +80.9% |
| Line Item | 2025-06-30 | Y/Y |
|---|---|---|
| Cash & Equivalents | $97.7M | +92.2% |
| Accounts Receivable | $33K | -85.6% |
| Current Assets | $98.5M | +90.7% |
| Total Assets | $99.6M | +90.8% |
| Current Liabilities | $1.8M | -63.4% |
| Total Liabilities | $2.3M | -53.7% |
| Stockholders' Equity | $97.3M | +105.9% |
| Line Item | 2025-06-30 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$23.6M | -21.6% |
| Capital Expenditures | $18K | -89.9% |
| Investing Cash Flow | -$18K | +89.9% |
| Financing Cash Flow | $70.5M | +3.6% |
| Free Cash Flow | -$23.6M | -20.5% |